These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32361585)

  • 1. Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants.
    Yao K; Liu H; Liu P; Liu W; Yang J; Wei Q; Cao P; Lai Y
    Comput Biol Chem; 2020 Jun; 86():107261. PubMed ID: 32361585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrative computational approach for the identification of dual inhibitors of isocitrate dehydrogenase 1 and 2 from phytocompounds of
    Bello RO; Okunlola ST; Kumar N; Victor O; Jimoh TO; Abdulsalam ZN; Kehinde IO; Umar HI
    J Biomol Struct Dyn; 2024 Sep; 42(14):7272-7288. PubMed ID: 37559488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy.
    Murali P; Karuppasamy R
    J Mol Model; 2022 Dec; 29(1):6. PubMed ID: 36484830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new IDH2
    Chen X; Wu X; Gao J; Ying H; Dong X; Che J; Shen Z
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000063. PubMed ID: 33184958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple e-pharmacophore modelling pooled with high-throughput virtual screening, docking and molecular dynamics simulations to discover potential inhibitors of Plasmodium falciparum lactate dehydrogenase (PfLDH).
    Saxena S; Durgam L; Guruprasad L
    J Biomol Struct Dyn; 2019 Apr; 37(7):1783-1799. PubMed ID: 29718775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
    Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
    J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
    Che J; Huang F; Zhang M; Xu G; Qu B; Gao J; Chen B; Zhang J; Ying H; Hu Y; Hu X; Zhou Y; Gao A; Li J; Dong X
    Eur J Med Chem; 2020 Oct; 203():112491. PubMed ID: 32679449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies.
    Ekhteiari Salmas R; Unlu A; Bektaş M; Yurtsever M; Mestanoglu M; Durdagi S
    J Biomol Struct Dyn; 2017 Jul; 35(9):1899-1915. PubMed ID: 27315035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.
    Wang Z; Zhang Z; Li Y; Sun L; Peng D; Du D; Zhang X; Han L; Zhao L; Lu L; Du H; Yuan S; Zhan M
    Acta Pharm Sin B; 2021 Jun; 11(6):1526-1540. PubMed ID: 34221866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
    Urban DJ; Martinez NJ; Davis MI; Brimacombe KR; Cheff DM; Lee TD; Henderson MJ; Titus SA; Pragani R; Rohde JM; Liu L; Fang Y; Karavadhi S; Shah P; Lee OW; Wang A; McIver A; Zheng H; Wang X; Xu X; Jadhav A; Simeonov A; Shen M; Boxer MB; Hall MD
    Sci Rep; 2017 Oct; 7(1):12758. PubMed ID: 28986582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors.
    Kumar R; Garg P; Bharatam PV
    J Biomol Struct Dyn; 2015; 33(5):1082-93. PubMed ID: 24875451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
    El Kerdawy AM; Osman AA; Zaater MA
    J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
    Lee WY; Chen KC; Chen HY; Chen CY
    Biomed Res Int; 2014; 2014():364625. PubMed ID: 24995286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel discoidin domain receptor 1 (DDR1) inhibitors using E-pharmacophore modeling, structure-based virtual screening, molecular dynamics simulation and MM-GBSA approaches.
    Nada H; Lee K; Gotina L; Pae AN; Elkamhawy A
    Comput Biol Med; 2022 Mar; 142():105217. PubMed ID: 35032738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-based pharmacophore modeling of TNF-α to design novel inhibitors using virtual screening and molecular dynamics.
    Jade DD; Pandey R; Kumar R; Gupta D
    J Biomol Struct Dyn; 2022 Mar; 40(4):1702-1718. PubMed ID: 33034255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
    Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
    J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3D-QSAR, Scaffold Hopping, Virtual Screening, and Molecular Dynamics Simulations of Pyridin-2-one as mIDH1 Inhibitors.
    Wang Y; Jia S; Wang F; Jiang R; Yin X; Wang S; Jin R; Guo H; Tang Y; Wang Y
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors.
    Deniz U; Ozkirimli E; Ulgen KO
    J Mol Graph Model; 2016 Jan; 63():110-24. PubMed ID: 26724452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.